Sugi Predict

Sugi Predict / Targets / CYP4F3

CYP4F3

Cytochrome P450 4F3 · Q08477 · CYP4F3 on Sugi Atlas →

6,781 patent compounds predicted against CYP4F3, 4,369 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2753072 SCHEMBL2753072 0.56 3/20
SCHEMBL2752346 SCHEMBL2752346 0.52 3/20
SCHEMBL2752131 SCHEMBL2752131 0.52 3/20
SCHEMBL1165314 SCHEMBL1165314 0.47 3/20
SCHEMBL971260 SCHEMBL971260 0.42 3/20
SCHEMBL2749440 SCHEMBL2749440 0.42 3/20
SCHEMBL2752725 SCHEMBL2752725 0.41 3/20
SCHEMBL2091704 SCHEMBL2091704 0.41 3/20
SCHEMBL971261 SCHEMBL971261 0.40 3/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2566375) 0.90 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2592428) 0.90 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2570005) 0.89 2/20
SCHEMBL2584612 SCHEMBL2584612 0.79 2/20
SCHEMBL2407878 SCHEMBL2407878 0.74 2/20
SCHEMBL196765 SCHEMBL196765 0.73 2/20
SCHEMBL2580241 SCHEMBL2580241 0.72 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2592437) 0.70 2/20
SCHEMBL2582318 SCHEMBL2582318 0.68 2/20
SCHEMBL1180429 SCHEMBL1180429 0.67 2/20
SCHEMBL1181635 SCHEMBL1181635 0.67 2/20

Clinical trials — most relevant to CYP4F3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
OPTImization of the Dose of tacroliMUS by Bayesian Prediction PHASE4COMPLETED
Effect of Genetic Polymorphisms of UGT on the PKs of Indapamide in Egyptians PHASE4UNKNOWN
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity PHASE4COMPLETED
Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG PHASE4UNKNOWN
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer PHASE1/PHASE2COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma PHASE2NOT_YET_RECRUITING
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects PHASE1NOT_YET_RECRUITING
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer PHASE1COMPLETED
Drug-Drug Interaction (DDI) Study in Healthy Volunteers PHASE1COMPLETED
Alcohol Inhibits Drug Metabolism by Carboxylesterases PHASE1COMPLETED
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer PHASE1ACTIVE_NOT_RECRUITING
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer nanCOMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia nanNOT_YET_RECRUITING
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients nanCOMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
The Study of Warfarin Maintenance Dose in Chinese Patients nanUNKNOWN
Effects of Genotype on CYP2C9 Drug Interactions nanCOMPLETED
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant nanRECRUITING
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease nanCOMPLETED
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6 nanCOMPLETED
Pharmacogenetic Determinants Of Treatment Response In Children nanRECRUITING
Individualized Antiretroviral Therapy nanCOMPLETED
Optimisation of Nutrition and Medication for Acutely Admitted Older Medical Patients nanUNKNOWN
Blood Levels of Ketamine in Patients Using Topical Application of 10% Ketamine Gel for Neuropathic Pain nanUNKNOWN
Aromatase Inhibitor Clinical Trial nanUNKNOWN
Pharmacogenetic Dosage Algorithm for Acenocoumarol nanCOMPLETED
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen nanUNKNOWN
Omeprazole and Famotidine in Chronic Dysfunction of the Transplanted Kidney nanUNKNOWN
Developmental Regulation of Proteins Responsible for Transforming Drugs in the Body nanCOMPLETED
Evaluation of Primex's PGX Assay to Assess the Clinical Utility of Pharmacogenomics nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYP4F3 binder may also engage these)

ProteinNameSimilarity
CYP4F2 Cytochrome P450 4F2 1.000 landscape →
P33274 — 0.998 P33274 →
CYP4F8 Cytochrome P450 4F8 0.998 landscape →
Q9EP75 — 0.997 Q9EP75 →
P51869 — 0.997 P51869 →
P51870 — 0.994 P51870 →
CYP4Z1 Cytochrome P450 4Z1 0.994 landscape →
Q6NT55 — 0.994 Q6NT55 →
Q6ZWL3 — 0.993 Q6ZWL3 →
CYP4F11 Cytochrome P450 4F11 0.993 landscape →
P51871 — 0.993 P51871 →
Q3MID2 — 0.992 Q3MID2 →
Q6A152 — 0.991 Q6A152 →
Q99N16 — 0.990 Q99N16 →
CYP4F12 Cytochrome P450 4F12 0.990 landscape →
P15128 — 0.990 P15128 →
P15129 — 0.990 P15129 →
A2RRT9 — 0.989 A2RRT9 →
CYP4X1 Cytochrome P450 4X1 0.988 landscape →
Q9GLL1 — 0.988 Q9GLL1 →
P20816 — 0.987 P20816 →
Q64462 — 0.987 Q64462 →
Q9VXY0 — 0.987 Q9VXY0 →
P08516 — 0.986 P08516 →
P20817 — 0.986 P20817 →
Q5RCN6 — 0.985 Q5RCN6 →
P24464 — 0.984 P24464 →
P24456 — 0.984 P24456 →
CYP2R1 Vitamin D 25-hydroxylase (EC 1.14.14.24) (Cyt 0.984 landscape →
Q8K4D6 — 0.983 Q8K4D6 →